BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Bavarian leader questions Germany's Eurovision participation - 2Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- 3The Specialty of Compromise: Examples from Reality
- 4Banks for High Fixed Store Rates: Augment Your Investment funds
- 5Vote In favor of Your Favored Kind Of Cheddar
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- The Best Computer games for Multiplayer Fun
- Investigate These Retreats Well known With Seniors
- Vote in favor of your Number one Kind of Gems
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Hot Electric Vehicles for 2023
- Emotional wellness Matters: My Fight with Tension
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- 6 Famous kind of practice on the planet
